Novartis: Neoplasms trials
The registry lists 121 Neoplasms studies with Novartis as lead sponsor. 2 are open to participants now and 40 have results posted.
Phase 1 60Phase 2 40Phase 3 18Phase 4 7No phase 4(a study in two phases counts in both)
Studies
Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell LymphomaCompletedNCT00412997Phase 1
- Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in JapanCompletedNCT00412789Phase 1
- Study To Assess Long Term Safety Of PazopanibCompletedNCT00387205Phase 1
- Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate CancerCompletedNCT00375648Phase 3
- Efficacy of Octreotide Treatment in Patients With Primary Inoperable ThymomaCompletedNCT00332969Phase 2
- Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic CancerCompletedNCT00329368Phase 1
- Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)CompletedNCT00308269Phase 1
- Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal CancerCompletedNCT00262990Phase 3
- Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone MetastasisCompletedNCT00241111Phase 4
- Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone LesionsCompletedNCT00171964Phase 4
- Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced CancerCompletedNCT00171587Phase 1/2
- Study of Oral AEE788 in Adults With Advanced CancerCompletedNCT00118456Phase 1
- STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced DiarrheaCompletedNCT00050635Phase 4
- EPO906 in Carcinoid and Other Neuroendocrine TumorsCompletedNCT00050349Phase 2
- EPO906 Therapy in Patients With Advanced Kidney CancerCompletedNCT00035243Phase 2
- EPO906 Therapy in Patients With Advanced MelanomaCompletedNCT00035165Phase 2
- EPO906 Therapy in Patients With Advanced Breast CancerCompletedNCT00035126Phase 2
- EPO906 Therapy in Patients With Prostate CancerCompletedNCT00035113Phase 2
- EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal CancerCompletedNCT00035100Phase 2
- EPO906 Therapy in Patients With Advanced Colorectal CancerCompletedNCT00035087Phase 2
- Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1